EA201491005A1 - Устойчивые составы с контролируемым высвобождением - Google Patents
Устойчивые составы с контролируемым высвобождениемInfo
- Publication number
- EA201491005A1 EA201491005A1 EA201491005A EA201491005A EA201491005A1 EA 201491005 A1 EA201491005 A1 EA 201491005A1 EA 201491005 A EA201491005 A EA 201491005A EA 201491005 A EA201491005 A EA 201491005A EA 201491005 A1 EA201491005 A1 EA 201491005A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- low viscosity
- compositions
- carbon
- forming
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Настоящее изобретение относится к композициям, образующим нежидкокристаллическую смесь с низкой вязкостью: а) от 25 до 55 мас.% по меньшей мере одного диацилглицерина и/или по меньшей мере одного токоферола; b) от 25 до 55 мас.% по меньшей мере одного фосфолипидного компонента, содержащего фосфолипиды, которые имеют: i) полярные концевые группы, содержащие более чем 50% фосфатидилэтаноламина, и ii) две ацильные цепи, каждая из которых независимо имеет от 16 до 20 атомов углерода, отличающиеся тем, что по меньшей мере одна ацильная цепь имеет по меньшей мере одну ненасыщенную связь в углеродной цепи иприсутствуют не более чем четыре ненасыщенные связи в двух углеродных цепях; с) от 5 до 25 мас.% по меньшей мере одного биосовместимого, кислородсодержащего, органического растворителя с низкой вязкостью; отличающаяся тем, что в смеси с низкой вязкостью растворяют или диспергируют от 0,1 до 10 мас.% по меньшей мере одного пептидного активного средства, содержащего по меньшей мере один агонист рецептора соматостатина; а также отличающаяся тем, что субстанция-кандидат образует или способна образовать по меньшей мере одну неламеллярную жидкокристаллическую фазовую структуру при контакте с жидкостью на водной основе. Изобретение также относится к способам обработки, включающим введение подобной композиции, и предварительно заполненному устройству для введения и наборам, содержащим составы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566851P | 2011-12-05 | 2011-12-05 | |
| PCT/EP2012/073841 WO2013083459A1 (en) | 2011-12-05 | 2012-11-28 | Robust controlled-release peptide formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491005A1 true EA201491005A1 (ru) | 2014-11-28 |
| EA027924B1 EA027924B1 (ru) | 2017-09-29 |
Family
ID=47226199
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491005A EA027924B1 (ru) | 2011-12-05 | 2012-11-28 | Композиция-прекурсор, содержащая агонист рецептора соматостатина, способ ее получения, способ лечения путем ее введения и содержащее ее предварительно заполненное устройство введения |
| EA201490921A EA028040B1 (ru) | 2011-12-05 | 2012-11-28 | Композиция-предшественник, которая образует жидкокристаллическую композицию in vivo, способ доставки биологически активного средства с ее использованием, способ ее получения и способ лечения путем ее введения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490921A EA028040B1 (ru) | 2011-12-05 | 2012-11-28 | Композиция-предшественник, которая образует жидкокристаллическую композицию in vivo, способ доставки биологически активного средства с ее использованием, способ ее получения и способ лечения путем ее введения |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9555118B2 (ru) |
| EP (2) | EP2787975B1 (ru) |
| JP (2) | JP6081480B2 (ru) |
| KR (2) | KR101979051B1 (ru) |
| CN (2) | CN104093399B (ru) |
| AU (2) | AU2012348641B2 (ru) |
| BR (2) | BR112014013693B1 (ru) |
| CA (2) | CA2858227C (ru) |
| CL (1) | CL2014001472A1 (ru) |
| CO (1) | CO7000746A2 (ru) |
| DK (2) | DK2787975T3 (ru) |
| EA (2) | EA027924B1 (ru) |
| ES (2) | ES2645345T3 (ru) |
| HK (2) | HK1201722A1 (ru) |
| HR (1) | HRP20170954T1 (ru) |
| IL (2) | IL232789B (ru) |
| MX (2) | MX352024B (ru) |
| PE (1) | PE20141297A1 (ru) |
| PL (1) | PL2787975T3 (ru) |
| SG (1) | SG11201402673YA (ru) |
| SI (1) | SI2787974T1 (ru) |
| WO (2) | WO2013083460A1 (ru) |
| ZA (1) | ZA201403793B (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| SG194865A1 (en) * | 2011-05-25 | 2013-12-30 | Camurus Ab | Controlled release peptide formulations |
| US11672843B2 (en) * | 2012-05-25 | 2023-06-13 | Camurus Ab | Somatostatin receptor agonist formulations |
| PL2877155T3 (pl) | 2012-07-26 | 2021-05-17 | Camurus Ab | Formulacje opioidowe |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| CA2928407A1 (en) | 2013-10-22 | 2015-04-30 | Prolynx Llc | Conjugates of somatostatin and its analogs |
| US10722462B2 (en) | 2014-12-10 | 2020-07-28 | Council Of Scientific And Industrial Research | Discontinuous reverse micellar composition in cubic FD3M phase for sustained release of therapeutic drugs |
| WO2016102683A1 (en) * | 2014-12-23 | 2016-06-30 | Camurus Ab | Controlled-release formulations |
| GB201516554D0 (en) * | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
| ITUB20160416A1 (it) * | 2016-01-28 | 2017-07-28 | Italfarmaco Spa | Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma |
| BR112018069591A2 (pt) * | 2016-03-31 | 2019-04-16 | Sun Pharma Advanced Research Company Limited | gel viscoelástico e método para o controle de níveis de glicose no sangue |
| MX2019002999A (es) * | 2016-09-15 | 2019-07-18 | Camurus Ab | Formulaciones de analogo de prostaciclina. |
| JP7138626B2 (ja) * | 2016-09-27 | 2022-09-16 | カムルス エービー | アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤 |
| US10779576B2 (en) | 2017-05-24 | 2020-09-22 | VMR Products, LLC | Flavor disk |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| MX2020011535A (es) * | 2018-05-01 | 2020-11-24 | Chibi Inc | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |
| JP2021523223A (ja) | 2018-05-01 | 2021-09-02 | チビ，インコーポレイティド | 眼への薬物の非侵襲的な持続型送達のための液体デポー |
| CN108498849B (zh) * | 2018-05-08 | 2021-04-30 | 武汉百纳礼康生物制药有限公司 | 一种液晶凝胶肝动脉栓塞剂及其制备方法 |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| EP3975991A1 (en) | 2019-05-29 | 2022-04-06 | Camurus AB | Lipid-controlled release compositions |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
| WO2022093722A1 (en) * | 2020-10-27 | 2022-05-05 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
| CN113081954A (zh) * | 2021-05-25 | 2021-07-09 | 南昌大学第二附属医院 | 一种凝胶载药贴剂药物输送*** |
| CN117794519A (zh) * | 2021-07-27 | 2024-03-29 | 法纳克斯株式会社 | 非层状液晶形成性组合物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8206744D0 (sv) | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | Preparat for kontrollerad avgivning av substanser |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| WO1995026715A2 (en) * | 1994-03-30 | 1995-10-12 | Dumex-Alpharma A/S | Use of fatty acid esters as bioadhesive substances |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| CA2219698C (en) | 1996-10-31 | 2007-09-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| JP3952617B2 (ja) | 1998-12-11 | 2007-08-01 | 株式会社日立製作所 | 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒 |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| EP1689444A4 (en) | 2003-10-24 | 2007-08-08 | Univ Saskatchewan | DNA DISSIPATION WITH GEMINI CATIONIC TENSIDES |
| PL1682091T3 (pl) | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| WO2006075124A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
| US8182834B2 (en) | 2004-01-23 | 2012-05-22 | Camurus Ab | Ternary non-lamellar lipid compositions |
| GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
| SG173326A1 (en) * | 2004-06-04 | 2011-08-29 | Camurus Ab | Liquid depot formulations |
| WO2006002050A1 (en) * | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
| JP5144277B2 (ja) | 2005-01-14 | 2013-02-13 | カムルス エービー | 局所用生体付着性製剤 |
| US9060935B2 (en) | 2005-01-21 | 2015-06-23 | Camurus Ab | Pharmaceutical lipid compositions |
| DK1888031T3 (da) | 2005-06-06 | 2013-02-18 | Camurus Ab | GLP-1-analogformuleringer |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
-
2012
- 2012-11-28 US US14/362,542 patent/US9555118B2/en active Active
- 2012-11-28 PL PL12791490T patent/PL2787975T3/pl unknown
- 2012-11-28 CN CN201280066168.1A patent/CN104093399B/zh active Active
- 2012-11-28 EA EA201491005A patent/EA027924B1/ru not_active IP Right Cessation
- 2012-11-28 CN CN201280066173.2A patent/CN104105479B/zh active Active
- 2012-11-28 AU AU2012348641A patent/AU2012348641B2/en active Active
- 2012-11-28 SG SG11201402673YA patent/SG11201402673YA/en unknown
- 2012-11-28 AU AU2012348640A patent/AU2012348640B2/en active Active
- 2012-11-28 MX MX2014006625A patent/MX352024B/es active IP Right Grant
- 2012-11-28 DK DK12791490.1T patent/DK2787975T3/da active
- 2012-11-28 JP JP2014545179A patent/JP6081480B2/ja active Active
- 2012-11-28 CA CA2858227A patent/CA2858227C/en active Active
- 2012-11-28 SI SI201230991T patent/SI2787974T1/sl unknown
- 2012-11-28 KR KR1020147018186A patent/KR101979051B1/ko active IP Right Grant
- 2012-11-28 PE PE2014000875A patent/PE20141297A1/es not_active Application Discontinuation
- 2012-11-28 KR KR1020147018578A patent/KR20140105527A/ko not_active Application Discontinuation
- 2012-11-28 US US14/362,517 patent/US9585959B2/en active Active
- 2012-11-28 EA EA201490921A patent/EA028040B1/ru not_active IP Right Cessation
- 2012-11-28 EP EP12791490.1A patent/EP2787975B1/en active Active
- 2012-11-28 WO PCT/EP2012/073843 patent/WO2013083460A1/en active Application Filing
- 2012-11-28 WO PCT/EP2012/073841 patent/WO2013083459A1/en active Application Filing
- 2012-11-28 CA CA2857982A patent/CA2857982A1/en not_active Abandoned
- 2012-11-28 JP JP2014545177A patent/JP6081479B2/ja active Active
- 2012-11-28 ES ES12791490.1T patent/ES2645345T3/es active Active
- 2012-11-28 BR BR112014013693-9A patent/BR112014013693B1/pt active IP Right Grant
- 2012-11-28 MX MX2014006624A patent/MX350929B/es active IP Right Grant
- 2012-11-28 BR BR112014013691A patent/BR112014013691A2/pt not_active Application Discontinuation
- 2012-11-28 ES ES12791208.7T patent/ES2629188T3/es active Active
- 2012-11-28 DK DK12791208.7T patent/DK2787974T3/en active
- 2012-11-28 EP EP12791208.7A patent/EP2787974B1/en active Active
-
2014
- 2014-05-23 ZA ZA2014/03793A patent/ZA201403793B/en unknown
- 2014-05-26 IL IL23278914A patent/IL232789B/en active IP Right Grant
- 2014-06-05 IL IL232967A patent/IL232967A0/en unknown
- 2014-06-05 CL CL2014001472A patent/CL2014001472A1/es unknown
- 2014-07-02 CO CO14142113A patent/CO7000746A2/es unknown
-
2015
- 2015-03-04 HK HK15102185.4A patent/HK1201722A1/xx unknown
- 2015-03-06 HK HK15102298.8A patent/HK1201735A1/xx unknown
-
2017
- 2017-06-23 HR HRP20170954TT patent/HRP20170954T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491005A1 (ru) | Устойчивые составы с контролируемым высвобождением | |
| CL2021000191A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| EA201391675A1 (ru) | Пептидные композиции с контролируемым высвобождением | |
| EA201791166A1 (ru) | Препараты с контролируемым высвобождением | |
| EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
| MX351430B (es) | Pre-concentrado lipídico de liberación sostenida de una sustancia farmacológicamente activa y una composición farmacéutica que comprende el mismo. | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| PH12015500936B1 (en) | Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| RU2014102940A (ru) | Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения | |
| MX2018003333A (es) | Formulaciones de liberacion controlada. | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| BR112015032572A2 (pt) | composições e métodos para melhorar o desempenho durante exercícios | |
| TN2014000483A1 (en) | Somatostatin receptor agonist formulations | |
| MX2019002999A (es) | Formulaciones de analogo de prostaciclina. | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon | |
| EA201592297A1 (ru) | Композиции агомелатина, содержащие агомелатин в форме сокристаллов | |
| BR112018000525A2 (pt) | concentrado contendo alprostadil | |
| BR112018001637A2 (pt) | concentrado contendo alprostadil | |
| EA201491453A1 (ru) | Неводная жидкая композиция | |
| UA97030U (uk) | Спосіб підвищення захисних властивостей ліпіну (фосфатидилхоліну) | |
| AR078735A1 (es) | Una solucion de droga de taxanos que comprende un solubilizante y su metodo de preparacion | |
| RS116004A (en) | Diclofenack stick and procedure for its obtaining |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |